Director/PDMR Shareholding

RNS Number : 0317D
Ergomed plc
14 February 2020
 

 PRESS RELEASE

 

 

Ergomed Plc

("Ergomed" or the "Company")

 

Directors' Dealings

 

 

Guildford, UK - 14 February 2020 - Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces the purchase of ordinary  shares of 1 pence each ("Shares") by four Directors of the Company.

 

PDMR

Position

Shares acquired

Purchase price (£)

Date of purchase

Resultant shareholding in the Company (Shares)

Rolf Soderstrom(1)

Non-Executive Director

10,000

4.56

11 February 2020

10,000

Dr Jim Esinhart

Non-Executive Director

10,000

4.56

11 February 2020

10,000

Ian Johnson

Non-Executive Director

10,000

4.56

11 February 2020

10,000

Lewis Cameron

Chief Operating Officer

10,910

4.56

12 February 2020

10,910

 

(1)   Note: includes Shares acquired by Linda Davey, being a person closely associated with Rolf Soderstrom.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated ("PCA") with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Rolf Soderstrom

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed Plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 GB00BN7ZCY67

b)

Nature of the transaction

Purchase of Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

£4.56

5,000



e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

Volume: 5,000 ordinary shares of 1 pence each, purchase price of 456 pence per share

Aggregated: £22,800.00

 

f)

Date of the transaction

11 February 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Linda Davey

2

Reason for the notification

a)

Position/status

PCA with Rolf Soderstrom, Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed Plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 GB00BN7ZCY67

b)

Nature of the transaction

Purchase of Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

£4.56

5,000



e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

Volume: 5,000 ordinary shares of 1 pence each, purchase price of 456 pence per share

Aggregated: £22,800.00

 

f)

Date of the transaction

11 February 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jim Esinhart, PhD

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed Plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 GB00BN7ZCY67

b)

Nature of the transaction

Purchase of Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

£4.56

10,000



e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

Volume: 10,000 ordinary shares of 1 pence each, purchase price of 456 pence per share

Aggregated: £45,600.00

 

f)

Date of the transaction

11 February 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Ian Johnson

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed Plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

GB00BN7ZCY67

b)

Nature of the transaction

Purchase of Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

£4.56

10,000



e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

Volume: 10,000 ordinary shares of 1 pence each, purchase price of 456 pence per share

Aggregated: £45,600.00

 

 

f)

Date of the transaction

11 February 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Lewis Cameron

2

Reason for the notification

a)

Position/status

Chief Operating Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed Plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

GB00BN7ZCY67

b)

Nature of the transaction

Purchase of Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

£4.56

10,910



e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

Volume: 10,910 ordinary shares of 1 pence each, purchase price of 456 pence per share

Aggregated: £49,749.60

 

f)

Date of the transaction

12 February 2020

g)

Place of the transaction

London Stock Exchange, AIM

 

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)




Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

ergomed@consilium-comms.com

Matthew Neal / Olivia Manser




 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHKZGMZVDZGGZG

Companies

Ergomed (ERGO)
UK 100

Latest directors dealings